CytRx recently announced that it had filed an S-1 with the Securities and Exchange Commission (SEC) for its majority-owned subsidiary RXi Pharmaceuticals for a public offering. RXi is focused on...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)